A Biomarker Screening Protocol for Participants With Solid Tumors
Public ClinicalTrials.gov record NCT05891197. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Biomarker Screening Protocol to Support Preliminary Eligibility for Clinical Trials Evaluating Safety and Efficacy of Adoptive T-cell Therapies in Participants With Solid Tumors
Study identification
- NCT ID
- NCT05891197
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Lyell Immunopharma, Inc.
- Industry
- Enrollment
- 10 participants
Conditions and interventions
Conditions
- Advanced Breast Cancer
- Advanced Lung Carcinoma
- Endometrial Cancer
- Endometrioid Tumor
- Fallopian Tube Cancer
- High Grade Serous Carcinoma
- NSCLC
- NSCLC Stage IV
- NSCLC, Recurrent
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
- Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Non-small Cell Lung Cancer
- Ovarian Cancer
- Ovarian Epithelial Cancer
- Platinum-resistant Ovarian Cancer
- Primary Peritoneal Carcinoma
- Recurrent Breast Cancer
- Recurrent NSCLC
- Relapse/Recurrence
- Relapsed Cancer
- Triple Negative Breast Cancer
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 18, 2023
- Primary completion
- Feb 4, 2025
- Completion
- Feb 4, 2025
- Last update posted
- Jun 30, 2025
2023 – 2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Accellacare | Rocky Mount | North Carolina | 27804 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05891197, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05891197 live on ClinicalTrials.gov.